Related Experiment Video
Updated: Oct 6, 2025
09:34
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
9.1K
Novel Selectively Targeted Multifunctional Nanostructured Lipid Carriers for Prostate Cancer Treatment
Lital Cohen1, Yehuda G Assaraf2, Yoav D Livney1
1The Laboratory of Biopolymers for Food and Health, Department of Biotechnology and Food Engineering, Technion-Israel Institute of Technology, Haifa 3200003, Israel.
Pharmaceutics
|January 21, 2022
Summary
We developed targeted nanoparticles for prostate cancer (PC) treatment. These nanoparticles deliver chemotherapy drugs directly to cancer cells, showing higher potency and fewer side effects than traditional methods.
Area of Science:
- Oncology
- Nanotechnology
- Drug Delivery
Background:
- Prostate cancer (PC) is a leading malignancy in men over 50.
- Current chemotherapy for PC has limited efficacy due to poor drug solubility, low tumor specificity, and acquired resistance.
- Nanoparticle-based drug delivery offers a promising strategy to overcome these limitations.
Purpose of the Study:
- To develop novel, selectively PC-targeted nanoparticles for enhanced chemotherapy delivery.
- To utilize PEGylated nanostructured lipid carriers (NLCs) decorated with prostate-specific membrane antigen (PSMA) ligands.
- To encapsulate the cytotoxic drug cabazitaxel (CTX) for targeted delivery.
Main Methods:
- Formulation of PEGylated NLCs loaded with cabazitaxel (CTX).
- Characterization of nanoparticle size, drug loading capacity, encapsulation efficiency, and in vitro drug release.
- Evaluation of selective cellular uptake in PSMA-overexpressing PC cells.
- Assessment of in vitro cytotoxicity and growth inhibition compared to free drug.
Main Results:
- NLCs exhibited high cabazitaxel loading (168 ± 3 mg/g) and encapsulation efficiency (67 ± 1%) with an average diameter of 159 ± 3 nm.
- The nanoparticles demonstrated sustained drug release and selective internalization into PSMA-positive PC cells.
- Targeted NPs showed potent, dose-dependent growth inhibition at picomolar concentrations, significantly outperforming free cabazitaxel.
Conclusions:
- The developed PSMA-targeted NLCs represent an effective nano-delivery platform for prostate cancer.
- This targeted approach promises enhanced therapeutic efficacy with reduced systemic toxicity.
- Further investigation into this platform could lead to improved treatment strategies for prostate cancer.
